$170.7 K

OBMP Mkt cap, 24-Nov-2020
OncBioMune Pharmaceuticals Net income (Q1, 2020)-5.1 M
OncBioMune Pharmaceuticals EBIT (Q1, 2020)-324.2 K
OncBioMune Pharmaceuticals Cash, 31-Mar-20202 K
OncBioMune Pharmaceuticals EV3.8 M

OncBioMune Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

781.1k77.9k24.0

Cost of goods sold

219.4k52.4k

Gross profit

561.6k25.6k

Gross profit Margin, %

72%33%

Sales and marketing expense

339.0k33.1k

R&D expense

52.1k85.3k94.4k103.9k204.6k166.7k

General and administrative expense

62.6k77.7k198.1k182.2k214.2k225.2k174.3k189.4k

Operating expense total

401.6k110.8k250.2k267.5k308.6k329.1k378.8k356.1k

Depreciation and amortization

17.4k

EBIT

(565.9k)(807.6k)(1.8m)(2.5m)(1.8m)(1.8m)

EBIT margin, %

(2358008%)

Interest expense

22.6k45.8k

Income tax expense

Net Income

(952.5k)(315.9k)(757.4k)(990.4k)(2.0m)(20.5m)6.5m(9.4m)

OncBioMune Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

198.4k88.7k198.1k65.2k31.4k200.0k56.4k62.5k8.9k38.6k16.9k10.4k4.6k184.6k366.5k12.8k10.6k142.5k111.9k83.6k2.1k2.2k50.3k136.1k2.0k

Accounts Receivable

30.6k56.1k94.1k65.7k40.2k170.0k94.1k93.4k

Prepaid Expenses

13.8k21.2k12.9k14.6k17.3k14.3k21.1k4.7k89.04.5k97.03.7k39.5k76.7k45.3k69.7k75.6k99.6k240.8k17.4k226.2k203.9k189.7k235.3k27.1k

Inventories

100.4k96.6k52.6k104.6k106.2k

Current Assets

343.3k262.6k305.2k1.1m793.2k214.2k77.6k67.1k8.9k43.0k17.0k10.4k4.6k198.2k413.1k92.1k57.9k460.1k386.2k382.8k242.8k19.7k276.6k203.9k189.7k371.4k29.1k

PP&E

10.4k10.2k9.9k8.9k8.3k8.5k6.1k5.5k4.9k3.7k3.1k2.6k1.4k

Total Assets

1.1m1.0m1.0m1.8m1.5m489.2k428.2k615.9k322.9k339.5k17.0k10.4k4.6k204.6k429.9k108.6k74.2k5.2m5.1m397.7k255.3k31.6k287.9k264.4k240.7k412.9k30.5k

Accounts Payable

300.1k416.1k474.6k389.2k340.3k208.8k102.1k127.5k97.0k104.4k127.2k13.2k4.6k146.3k135.0k133.9k229.3k649.6k824.6k757.8k369.3k381.0k457.5k713.0k740.4k857.8k730.6k

Short-term debt

500.0k500.0k500.0k500.0k500.0k300.0k300.0k400.0k525.0k625.0k625.0k14.3k114.7k54.3k61.9k112.9k285.1k551.5k927.2k1.3m1.5m1.3m2.6m3.2m3.3m3.6m

Current Liabilities

576.2k855.8k1.1m37.5k14.6k251.1k254.1k444.8k433.6k3.3m3.1m4.1m5.4m9.8m10.5m11.7m13.1m14.1m21.0m

Long-term debt

67.5k54.3k57.7k98.7k99.2k99.2k99.2k14.8k5.9k

Total Debt

500.0k500.0k500.0k500.0k500.0k300.0k300.0k400.0k525.0k625.0k625.0k14.3k67.5k54.3k57.7k98.7k99.2k278.3k1.1m1.1m1.1m1.1m1.1m1.1m1.1m3.6m

Total Liabilities

800.1k916.1k974.6k889.2k840.3k508.8k1.0m1.1m11.8m13.1m14.1m21.0m

Common Stock

2.1k2.1k2.1k2.1k2.1k2.1k6.3k6.3k6.3k6.3k6.3k40.9k450.05.3k5.7k5.7k6.0k13.1k13.6k15.3k21.8k23.2k25.3k29.1k31.7k48.093.0

Preferred Stock

100.0100.0100.0100.0100.0

Additional Paid-in Capital

2.4m2.5m2.6m2.6m2.6m2.6m2.6m2.7m2.7m2.7m2.7m3.9m5.4m428.7k1.7m1.8m2.2m7.8m8.3m8.6m9.2m9.2m9.4m10.1m10.3m10.6m10.7m

Retained Earnings

(2.8m)(2.9m)(3.4m)(3.4m)(3.8m)(3.9m)(5.4m)(480.6k)(1.6m)(2.2m)(2.5m)(5.9m)(6.2m)(12.3m)(14.3m)(19.0m)(19.7m)(21.6m)(23.2m)(24.2m)(31.7m)

Total Equity

331.3k112.6k52.5k956.2k632.6k(19.6k)(148.1k)(239.8k)(713.9k)(712.9k)(1.1m)(27.2k)(10.0k)(46.5k)175.8k(336.2k)(359.5k)1.9m2.1m(3.7m)(5.2m)(9.8m)(10.2m)(11.5m)(12.9m)(13.7m)(21.0m)

Debt to Equity Ratio

1.5 x4.4 x9.5 x0.5 x0.8 x-15.3 x-2 x-1.7 x-0.7 x-0.9 x-0.6 x-1.5 x0.3 x-0.2 x-0.3 x0.1 x0.1 x-0.3 x-0.2 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.2 x

Debt to Assets Ratio

0.4 x0.5 x0.5 x0.3 x0.3 x0.6 x0.7 x0.6 x1.6 x1.8 x36.7 x0.3 x0.1 x0.5 x1.3 x0 x0.1 x2.7 x4.2 x34.2 x3.7 x4.1 x4.5 x2.6 x119.6 x

Financial Leverage

3.4 x9.1 x19.5 x1.9 x2.3 x-25 x-2.9 x-2.6 x-0.5 x-0.5 x0 x-0.4 x-0.5 x-4.4 x2.4 x-0.3 x-0.2 x2.8 x2.5 x-0.1 x0 x0 x0 x0 x0 x0 x0 x

OncBioMune Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(952.5k)(315.9k)(757.4k)(990.4k)(2.0m)(20.5m)6.5m(9.4m)

Depreciation and Amortization

88.3k86.5k17.4k274.01.1k3.7k2.3k2.3k

Accounts Receivable

(51.6k)15.9k

Inventories

15.0k2.2k

Accounts Payable

68.5k(158.8k)1.3k(23.1k)111.3k164.6k172.1k69.7k

Cash From Operating Activities

(606.2k)(637.6k)(372.2k)(851.8k)(1.5m)(2.3m)(1.7m)(1.2m)

Purchases of PP&E

(11.0k)(715.0)

Cash From Investing Activities

64.9k892.0k(152.3k)(6.3k)(20.5k)

Short-term Borrowings

(200.0k)(53.6k)(6.1k)(99.7k)

Long-term Borrowings

(91.0k)(96.4k)(415.8k)

Cash From Financing Activities

250.0k25.0k1.4m871.2k2.3m1.7m1.2m

Net Change in Cash

(291.3k)254.3k(499.5k)572.0k(672.8k)10.1k(1.2k)21.3k

Interest Paid

2.5k9.2k314.5k243.9k6.0k

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(768.2k)(1.0m)(325.0k)578.7k255.1k(81.1k)(209.6k)(376.4k)(93.1k)(92.1k)(438.7k)(195.0k)(1.7m)(341.8k)(444.3k)(1.0m)(1.4m)(2.8m)(3.0m)(9.1m)9.3m4.6m4.0m(4.4m)(6.1m)(7.0m)(5.1m)

Depreciation and Amortization

44.1k66.2k22.1k44.1k64.4k17.4k34.9k52.3k275.0549.0823.01.9k2.5k2.4k585.01.2k1.8k584.01.2k1.8k585.0

Accounts Receivable

24.5k(1.0k)12.5k40.9k66.4k50.6k(16.2k)51.6k53.5k

Inventories

7.3k11.0k2.2k2.2k2.2k(4.7k)(41.9k)(44.9k)

Accounts Payable

(14.3k)101.7k91.7k6.2k(42.7k)(15.3k)(2.6k)22.8k(9.1k)(1.6k)21.1k10.2k1.6k1.7k(56.8k)133.9k127.0k(420.0)148.7k89.1k(9.0k)2.8k79.3k162.7k190.1k307.5k118.5k

Cash From Operating Activities

(600.9k)(710.7k)(60.0k)(193.0k)(350.2k)(37.5k)(105.5k)(76.2k)(79.1k)(149.4k)(171.0k)(16.4k)(39.3k)(378.6k)(357.7k)(750.8k)(1.2m)(670.8k)(1.3m)(2.0m)(433.9k)(672.8k)(1.3m)(286.3k)(675.1k)(831.3k)(197.7k)

Purchases of PP&E

(715.0)(715.0)(715.0)

Cash From Investing Activities

123.5k(75.0k)(150.6k)(348.8k)4.7k38.4k(11.6k)(11.6k)

Short-term Borrowings

(200.0k)(200.0k)(200.0k)(30.8k)(664.0)(3.7k)(4.8k)(533.0)(533.0)(533.0)

Long-term Borrowings

(654.2k)

Cash From Financing Activities

250.0k250.0k(200.0k)(200.0k)(25.0k)75.0k175.0k175.0k20.0k37.0k457.7k51.4k90.8k493.0k771.7k1.4m2.1m434.5k673.6k1.3m286.1k674.9k967.2k178.3k

Net Change in Cash

(350.9k)(460.7k)(60.0k)(193.0k)(226.7k)(312.5k)(456.1k)(450.0k)(4.1k)25.6k4.0k3.6k(2.3k)83.8k(306.2k)(660.0k)(662.2k)139.2k106.0k96.6k637.0810.048.9k(201.0)(201.0)135.9k(19.4k)

Interest Paid

5.01.5k339.0339.04.1k4.1k17.1k62.1k62.7k484.2k1.8k3.3k3.3k1.6k

OncBioMune Pharmaceuticals Ratios

USDQ2, 2012

Debt/Equity

1.5 x

Debt/Assets

0.4 x

Financial Leverage

3.4 x